Alicia Secor

Alicia Secor serves as President and CEO of Atalanta Therapeutics since June 2019, focusing on pioneering RNAi treatments for neurodegenerative diseases. Secor has also held significant leadership roles, including Non-Executive Director on the Board of Orchard Therapeutics, where contributions were made to various committees until January 2024. Previously, Secor was a Board Member for the Foundation for Prader-Willi Research and served as a Non-Executive Director and Chair of the Compensation Committee at GW Pharmaceuticals, involved in its acquisition by Jazz Pharmaceuticals in May 2021. Leadership roles have included President and CEO at Juniper Pharmaceuticals, Chief Commercial Officer at Zafgen, and various senior positions at Genzyme, encompassing Vice President roles in different divisions. Alicia Secor holds an MBA from the D'Amore-McKim School of Business at Northeastern University and a BS in Health Administration from the University of New Hampshire.